The immunoengineering field is transforming cancer, autoimmunity, regeneration, and transplantation treatments by combining the diverse and complex fields of engineering and immunology. On March 4, 2025, the Johns Hopkins Translational ImmunoEngineering Center hosted its inaugural symposium to highlight some of the latest advances in immunoengineering with a focus on translational aspects of the field. It was also a celebration of center’s renewal and its accomplishments.
Keynote speakers included Michel Sadelain, Inaugural Director of the Columbia Initiative in Cell Engineering and Therapy and Robert Seder, Chief, Cellular Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH. Other speakers included the JH-TIE’s research team, Scott Carmer a biotech consultant, Ben Larman associate professor at Johns Hopkins Medicine, Kris Sachsenmeier from Compass Therapeutics, and Matt Tremblay from Blackbird Labs. Additionally, several Johns Hopkins students presented research as well.
The symposium enhances internal and external visibility to academic and industry stakeholders, while nucleating collaboration between students, post-doctoral scholars, investigators, clinicians, and industry scientists. These connections provide long-term value to all attendees.
The event was sponsored by JH-TIE an NIBIB funded NCBIB, National Center for Biomedical Imaging and Bioengineering, and supported by the JHU Provost’s office, JHUSOM, and Department of Pathology.